DM27, an enaminone, modifies the in vitro transport of antiviral therapeutic agents
- 6 May 2004
- journal article
- research article
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 25 (5) , 227-236
Abstract
Objective—For most antiviral drugs, low or variable bioavailability is attributed to poor absorption, susceptibility to efflux, or first pass metabolism. Enaminones are beta dicarbonyl compounds, which display P‐glycoprotein (P‐gp) substrate properties with high efflux ratios. This study investigates the influence of DM27, an enaminone, on the in vitro transport of antiviral agents and the possibility of using DM27 as a P‐gp inhibitor to prevent the efflux of certain antiretroviral agents.Methods—The transport of [3H]amprenavir, [3H]saquinavir, [3H]ritonavir, [14C]zidovudine (AZT) and [3H]acyclovir was evaluated across Caco‐2 cells with DM27 (10−10–10−4 M). In addition, the effect of DM27 (10−6 M) on the transport of transcellular and paracellular markers was tested to evaluate its influence on these transport pathways. The apparent permeability coefficient (Papp) for each drug or marker was calculated with/without DM27 and toxicity evaluation for DM27 was performed using the MTS assay.Results—The mean Papp for the investigated antiviral agents significantly increased by 22%–51% after DM27 incubation without any toxicity to the Caco‐2 cells. In addition, DM27 did not influence the transcellular or paracellular transport of propranolol and mannitol, respectively.Conclusions—DM27, an enaminone, increased the transport of antiretroviral drugs and acyclovir in a nontoxic manner without affecting the paracellular or transcellular transport of these drugs. This study suggests that DM27 may be used as a P‐gp efflux inhibitor to enhance the oral bioavailability of antiviral drugs and that drug–drug interactions will most probably be encountered upon co‐administration of P‐gp substrate drugs with enaminones. Copyright © 2004 John Wiley & Sons, Ltd.Keywords
This publication has 27 references indexed in Scilit:
- Multidrug Resistance and Anticonvulsants: New Studies with Some EnaminonesCurrent Medicinal Chemistry, 2004
- The influence of enaminones on the transport and oral bioavailability of P-glycoprotein substrate therapeutic agentsInternational Journal of Pharmaceutics, 2004
- Progress in understanding the structure–activity relationships of P-glycoproteinAdvanced Drug Delivery Reviews, 2002
- Role of P-glycoprotein in the renal transport of dideoxynucleoside analog drugsCanadian Journal of Physiology and Pharmacology, 1999
- Pharmacokinetics and Potential Interactions Amongst Antiretroviral Agents Used To Treat Patients with HIV InfectionClinical Pharmacokinetics, 1999
- The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.Journal of Clinical Investigation, 1998
- Protease Inhibitors in Patients with HIV DiseaseClinical Pharmacokinetics, 1997
- In Vitro techniques for studying drug metabolismJournal of Pharmacokinetics and Biopharmaceutics, 1996
- Synthesis and anticonvulsant activity of enaminones. 2. Further structure-activity correlationsJournal of Medicinal Chemistry, 1993
- The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987